Daniel E. Rees

Daniel’s experience includes the representation of:

Mergers & Acquisitions

• CoStar in its pending US$2.1 billion acquisition of Matterport and prior acquisitions of Homes.com and Homesnap
• Cerevel Therapeutics in its US$8.7 billion sale to AbbVie
• Icosavax in its US$1 billion sale to Astra Zeneca
• Prometheus Biosciences in its US$10.8 billion sale to Merck 
• Ironwood Pharmaceuticals in its US$1.1 billion acquisition of Swiss biotech VectivBio
• Switch in its US$11 billion take-private by Digital Bridge and IFM and US$420 million acquisition of Data Foundry
• LG Chem in its US$570 million acquisition of Aveo Oncology 
• Funds managed by PIMCO in the US$3.9 billion acquisition of Columbia Property Trust
• Amgen in its acquisition of Teneobio for up to US$2.5 billion in upfront cash and contingent regulatory milestones; and 20.5% stake investment in BeiGene for US$2.7 billion
• Alastin Skincare in its sale to Galderma
• Cryoport in its US$320 million acquisition of MVE Biological Solutions from Chart Industries and its US$275 million private placement of preferred and common equity with Blackstone
• Impact Biomedicines in its sale to Celgene for up to US$7 billion in upfront cash and contingent regulatory approval and sales-based milestones
• ICU Medical in its US$900 million acquisition of the Hospira Infusion Systems business of Pfizer
• Air Medical Resource Group in its sale to Air Medical Group Holdings
• Allergan in its:
  • US$40.5 billion Global Generic Pharmaceuticals Business sale to Teva
  • US$73 billion sale to Actavis
  • US$54 billion hostile takeover attempt by Valeant Pharmaceuticals International (and associated proxy contest lead by Pershing Square and Bill Ackman)
• PIMCO in its acquisition of Gurtin Municipal Bond Management
• ST Telemedia in CenturyLink’s US$34 billion acquisition of Level 3 Communications, Inc.
• J.P. Morgan as financial advisor to Intralinks Holdings in its US$821 million sale to Synchronoss Technologies
• Waypoint in its sale of its management platform to Starwood
• Ra Pharmaceuticals in its US$2.1 billion sale to UCB
• Akebia Therapeutics in its merger of equals with Keryx Biopharmaceuticals
• Aratana Therapeutics in its US$234 million sale to Elanco Animal Health
• Complete Production Services in its US$6.2 billion combination with Superior Energy Services
• Skrewball Whiskey in its majority stake sale to Pernod Ricard
• Golden State Foods in the sale of its McDonald’s food distribution business to Martin Brower
• Starbucks in the US$384 million sale of its Tazo tea business
• Incipio in its acquisition of Incase
• 5.11 Tactical in its acquisition of Beyond Clothing
• Paul Frank in its sale to Saban Brands
• T. Christy Enterprises in its sale to IPS Corporation
• California Creative Brands in its sale to Sabra

Capital Markets

• Cryoport in its follow-on offering of common stock
• ICU Medical in secondary offerings of common stock
• PDL BioPharma in its equity investment in, and dividend distribution of, Evofem Biosciences
• Landmark Infrastructure Partners LP in its IPO of common stock and other securities offerings
• Aratana Therapeutics in its IPO of common stock
• Skullcandy in its IPO of common stock
• Raptor Pharmaceutical and CoreCivic in “at-the-market” offerings of common stock
• CoreCivic in offerings of registered debt securities
• Realty Income Corporation in equity offerings of common stock
• CoreLogic in 144A offerings of senior notes
• Bank of America Merrill Lynch, Citigroup, Goldman Sachs, Jefferies, J.P. Morgan, Leerink, and Piper Jaffray in follow-on offerings or IPOs, by Corium, Inogen, Glaukos, Green Plains Renewable Energy, MAKO Surgical, Sientra, and YM BioSciences